About this trial
A multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. The phase 2 portion will be for patients with refractory/unresectable NF1-associated MPNST.
Eligibility criteria
Qualifiers
MFH/ undifferentiated pleomorphic sarcoma
Unclassified sarcoma
Rhabdomyosarcoma
Malignant peripheral nerve sheath tumor (MPNST)
Disqualifiers
A malignancy treated with curative intent and with no known active disease ≥5 years prior to study entry
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
Adequately treated carcinoma in situ without evidence of disease
Stable optic pathway glioma or low grade glioma not receiving active therapy
Trial design
Treatments tested in this trial
- Selumetinib + ZEN-3694 ± Durvalumab
Treatment groups
Sponsors and collaborators
University of Alabama at Birmingham
Lead sponsor
Congressionally Directed Medical Research Programs
Collaborator
Children's Hospital of Philadelphia
Collaborator